Last updated on May 2020

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)


Brief description of study

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). These patients are at high risk for progression of kidney disease, which can result in end-stage renal failure.

Clinical Study Identifier: NCT03841448

Find a site near you

Start Over

Clinical Trial Site

Lynwood, CA United States
  Connect »

Clinical Trial Site

Shreveport, LA United States
  Connect »

Clinical Trial Site

Hospitalet de Llobregat, Spain
  Connect »

Clinical Trial Site

Northridge, CA United States
  Connect »

Clinical Trial Site

Baltimore, MD United States
  Connect »

Clinical Trial Site

Charleston, SC United States
  Connect »

Clinical Trial Site

Clermont-Ferrand, France
  Connect »

Clinical Trial Site

Singapore, Singapore
  Connect »

Clinical Trial Site

Leicester, United Kingdom
  Connect »

Clinical Trial Site

London, United Kingdom
  Connect »

Clinical Trial Site

Rochester, MN United States
  Connect »

Clinical Trial Site

Madison, WI United States
  Connect »

Clinical Trial Site

Kuala Lumpur, Malaysia
  Connect »

Clinical Trial Site

Quezon City, Philippines
  Connect »

Clinical Trial Site

Taoyuan City, Taiwan
  Connect »

Clinical Trial Site

San Francisco, CA United States
  Connect »

Clinical Trial Site

Vancouver, BC Canada
  Connect »